Erlotinib Active Not Recruiting Phase 2 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01897480A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
NCT00553800Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer
NCT00977470Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
NCT01573702Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
NCT00137800Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients